JP7427308B2 - 網膜の神経細胞の保護剤 - Google Patents

網膜の神経細胞の保護剤 Download PDF

Info

Publication number
JP7427308B2
JP7427308B2 JP2023523431A JP2023523431A JP7427308B2 JP 7427308 B2 JP7427308 B2 JP 7427308B2 JP 2023523431 A JP2023523431 A JP 2023523431A JP 2023523431 A JP2023523431 A JP 2023523431A JP 7427308 B2 JP7427308 B2 JP 7427308B2
Authority
JP
Japan
Prior art keywords
cystamine
retinal
cells
mice
results
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023523431A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022249942A1 (https=
JPWO2022249942A5 (https=
Inventor
哲郎 山下
拓 尾▲崎▼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iwate University
Original Assignee
Iwate University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iwate University filed Critical Iwate University
Publication of JPWO2022249942A1 publication Critical patent/JPWO2022249942A1/ja
Publication of JPWO2022249942A5 publication Critical patent/JPWO2022249942A5/ja
Priority to JP2024004935A priority Critical patent/JP2024032794A/ja
Application granted granted Critical
Publication of JP7427308B2 publication Critical patent/JP7427308B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023523431A 2021-05-24 2022-05-18 網膜の神経細胞の保護剤 Active JP7427308B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024004935A JP2024032794A (ja) 2021-05-24 2024-01-17 網膜の神経細胞の保護剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2021086920 2021-05-24
JP2021086920 2021-05-24
JP2021172191 2021-10-21
JP2021172191 2021-10-21
PCT/JP2022/020635 WO2022249942A1 (ja) 2021-05-24 2022-05-18 網膜の神経細胞の保護剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024004935A Division JP2024032794A (ja) 2021-05-24 2024-01-17 網膜の神経細胞の保護剤

Publications (3)

Publication Number Publication Date
JPWO2022249942A1 JPWO2022249942A1 (https=) 2022-12-01
JPWO2022249942A5 JPWO2022249942A5 (https=) 2023-12-11
JP7427308B2 true JP7427308B2 (ja) 2024-02-05

Family

ID=84230063

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023523431A Active JP7427308B2 (ja) 2021-05-24 2022-05-18 網膜の神経細胞の保護剤
JP2024004935A Pending JP2024032794A (ja) 2021-05-24 2024-01-17 網膜の神経細胞の保護剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024004935A Pending JP2024032794A (ja) 2021-05-24 2024-01-17 網膜の神経細胞の保護剤

Country Status (3)

Country Link
JP (2) JP7427308B2 (https=)
TW (1) TWI901889B (https=)
WO (1) WO2022249942A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008122032A2 (en) 2007-04-02 2008-10-09 Benjamin Rubin Treatment method for mmp-implicated pathologies
JP2016540827A (ja) 2013-11-06 2016-12-28 ラプター ファーマシューティカルズ インコーポレイテッド ミトコンドリア疾患を治療するためのシステアミン及びその誘導体の使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008122032A2 (en) 2007-04-02 2008-10-09 Benjamin Rubin Treatment method for mmp-implicated pathologies
JP2016540827A (ja) 2013-11-06 2016-12-28 ラプター ファーマシューティカルズ インコーポレイテッド ミトコンドリア疾患を治療するためのシステアミン及びその誘導体の使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D'ONOFRIO, P. M. et. al.，MMP Inhibition Preserves Integrin Ligation and FAK Activation to Induce Survival and Regeneration in，IOVS，2019年，Vol.60, No.2，p.634-649
KUROSE, T. et al.，Neuroprotective Effect of a Dietary Supplement against Glutamate-induced Excitotoxicity in Retina，International Journal of Ophthalmology，2019年，Vol.12, No.8，p.1231-1237
MAHER, P. et al.，A Novel Approach to Enhancing Cellular Glutathione Levels，Journal of Neurochemistry，2008年，Vol.107，p.690-700
PAUL, B.D. et al.，Therapeucit Applications of Cyeteamine and Cystamine in Neurodegenerative and Neuropsychiatric Disea，Frontiers in Neurology，2019年，Vol.10, Article 1315，p.1-9
SUN, M. et al.，Down-Regulation of Matrix Metalloproteinase-9 by Pyrrolidine Dithiocarbamate Prevented Retinal Gangl，Current Eye Research，2011年，Vol.36, No.11，p.1053-1063

Also Published As

Publication number Publication date
JP2024032794A (ja) 2024-03-12
TWI901889B (zh) 2025-10-21
JPWO2022249942A1 (https=) 2022-12-01
WO2022249942A1 (ja) 2022-12-01
TW202312986A (zh) 2023-04-01

Similar Documents

Publication Publication Date Title
UA124698C2 (uk) Офтальмологічний розчин
CN106999543B (zh) 包含环孢霉素和海藻糖的眼用组合物
US20130317036A1 (en) Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions
JP2025069397A (ja) ブリモニジンとチモロールとを含む、緑内障罹患患者における眼圧を下降させるための組成物
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物
US10973758B2 (en) Methods of eye treatment using therapeutic compositions containing dipyridamole
JP6934581B2 (ja) エピナスチン又はその塩を含有する水性医薬組成物
JP7427308B2 (ja) 網膜の神経細胞の保護剤
JP7250685B2 (ja) ピリジルアミノ酢酸化合物を含有する医薬
TWI868659B (zh) 無防腐劑的眼科藥物乳劑及其應用
CN116897046A (zh) 含有熊去氧胆酸或其盐的水性医药组合物
TW304879B (https=)
JP2020514347A (ja) チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤
CN110200904B (zh) 一种降眼压缓释滴眼组合物及其制备方法
JPH07258083A (ja) 近視予防・治療剤
JP7723851B1 (ja) アトロピン含有水性医薬組成物
JPWO2006098292A1 (ja) 眼疾患治療剤
US11433096B2 (en) Ophthalmic formulation and methods of use
WO2025135087A1 (ja) 慢性移植片対宿主病における眼合併症の予防治療用医薬組成物
JP6764233B2 (ja) 眼疾患処置薬
WO2024135837A1 (ja) 組織移行性及び防腐効力を向上させるエピナスチン含有水性組成物
WO2024034592A1 (ja) Ｕｄｃａまたはその塩を含有する水性医薬組成物
TW202415402A (zh) 安定之肽組成物及使用彼以治療中度／重度乾眼相關性眼徵候之方法
JP2015229671A (ja) 網膜色素上皮細胞保護剤
CN116474105A (zh) 一种预防、缓解或治疗眼部疾病的药物组合物、制备方法及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231028

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231028

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240117

R150 Certificate of patent or registration of utility model

Ref document number: 7427308

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150